JAK2 and myelofibrosis: Fedratinib (TG101348) is a JAK2-selective inhibitor which demonstrated clinical benefits in patients with MF in early-phase clinical trials, and is approved by the Food and Drug Administration (FDA) as the first drug to treat myelofibrosis [9].